The Effect of Erythropoietin on Platelet Function and Fibrinolysis in Chronic Renal Failure
| Autor: | J Mehlsen, L.L. Jeppesen, J. Dalsgaard Nielsen, C Haedersdal, Doris Irene Stenver, Bo Friis Nielsen, K. Winther |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.medical_treatment Biomedical Engineering Medicine (miscellaneous) Bioengineering 030204 cardiovascular system & hematology Biomaterials 03 medical and health sciences 0302 clinical medicine Thrombin Internal medicine Fibrinolysis medicine Platelet Platelet activation business.industry General Medicine 030104 developmental biology Endocrinology Erythropoietin Hemodialysis Hemoglobin business Platelet factor 4 medicine.drug |
| Zdroj: | The International Journal of Artificial Organs. 17:141-145 |
| ISSN: | 1724-6040 0391-3988 |
| Popis: | The influence of erythropoietin therapy on platelet function and fibrinolysis was evaluated in 12 anemic hemodialysis patients. Six months of therapy with human erythropoietin (50 to 80 IU/kg initially) raised the hemoglobin level to 10.8 g/dl but did not increase platelet activity in vivo as measured by beta-thromboglobulin or platelet factor 4. There was no change in the platelet aggregation thresholds in vitro for ADP, adrenaline, thrombin or collagen during treatment. Platelet number and volume were also unaffected. Fibrinolytic activity intensified as erythropoietin treatment proceeded, with a fall of euglobulin clot lysis time and rise in the activity of t-PA. PAI-1 levels also showed a downward trend, without reaching significance. Thus erythropoietin treatment in modest doses does not seem to adversely influence the hemostatic system in patients on hemodialysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|